查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
NPS+(美国)-瀰漫大B细胞淋巴瘤
市场调查报告书
商品编码
1789647

NPS+(美国)-瀰漫大B细胞淋巴瘤

NPS+ (US) - Diffuse Large B-Cell Lymphoma
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2个工作天内

价格
简介目录

本报告探讨了瀰漫大B细胞淋巴瘤 (DLBCL) 治疗领域的竞争格局，并运用 NPS+ 框架对品牌健康度、忠诚度和处方行为进行了深入分析。报告检视了医师如何评估领先品牌、满意度和转换推动因素，以及最能引起共鸣的讯息。研究结果有助于揭示拥护者和流失拥护者对品牌的看法、影响处方价值的因素，以及增强市场地位的机会。

关键问题解答

  • 1.各品牌 NPS 评分比较
  • 2.医师对特定品牌的忠诚度如何？
  • 3.哪些品牌讯息能引起医师的共鸣？
  • 4.影响医师选择的关键因素有哪些？
  • 5.主要品牌的市占率
  • 6.主要品牌与竞争对手的比较
  • 7.因品牌满意度低而可能转换的品牌

主要品牌

  • Adcetris (brentuximab vedotin)
  • Brayangi (lisocabtagene maraleucel)
  • Columbi (glofitamab)
  • Epkinly/Tepkinly (依普利他单抗)
  • Kymriah (tisagenlecleucel)
  • Monjuvi/Minjuvi (他法西他单抗)
  • Porivee (polatuzumab vedotin)
  • Xpovio (serinexol)
  • Yescarta (axicabtagene ciloleucel)
  • Jinronta (loncustuximab tesirin)

方法论：

First View 报告是基于对透过 LiMATM 选出的医生进行的定量调查得出。 LiMATM 是全球最大的医生名录，已确认超过 300 万名医生。每位医生均根据严格的筛选标准精心挑选，以确保收集到的见解具有相关性和可靠性，反映顶尖医疗专业人士的真实意见和经验。调查结果以易于理解的图表形式呈现，方便您快速理解和分析数据。凭藉 LiMATM 的广泛覆盖范围和精准度，FirstView 报告提供无与伦比的数据驱动洞察，指导策略规划，帮助您在快速发展的医疗保健领域保持领先地位。

我们的报告有何独特之处？

FirstView 报告是值得信赖的行业领导者，专注于製药业，为生物製药专业人士和决策者提供深入、可操作的洞察。我们深厚的行业知识使我们能够提供相关且有价值的洞察，帮助您掌握新兴趋势，有​​效应对复杂课题。凭藉广泛的研究以及来自领先专家和关键意见领袖的独立、公正的见解，我们的报告可提供您所需的准确性和可靠性。独家访问独家访谈和数据，以及持续的市场监测，确保您全面了解市场动态。我们的报告涵盖 40 多个动态疾病领域、包括 KOL 洞察和定量医生调查在内的医生情报以及行业专家对医疗事务、数位健康、销售和营销、市场准入和其他领域问题的看法，使您能够做出更明智的、数据驱动的决策，并在快速变化的行业中保持竞争力。

简介目录

This report explores the competitive landscape for diffuse large B-cell lymphoma (DLBCL) therapies, providing a detailed analysis of brand health, loyalty, and prescribing behaviors through the NPS+ framework. It examines how physicians rate leading brands, the factors driving satisfaction and switching, and the messages that resonate most. The findings help clarify how brands are perceived by Promoters and Detractors, what influences prescribing value, and where opportunities exist to strengthen market position.

Key Questions Answered:

  • 1. How do NPS scores by brand compare?
  • 2. How loyal are physicians to specific brands?
  • 3. What brand messages resonate with physicians?
  • 4. What are the key factors driving physician choice?
  • 5. What is the market share of leading brands?
  • 6. How does each of the leading brands compare to its competitors?
  • 7. Which brands are vulnerable to switching due to low brand satisfaction?

Key Brands:

  • Adcetris (brentuximab vedotin)
  • Breyanzi (lisocabtagene maraleucel)
  • Columvi (glofitamab)
  • Epkinly/Tepkinly (epcoritamab)
  • Kymriah (tisagenlecleucel)
  • Monjuvi/Minjuvi (tafasitamab)
  • Polivy (polatuzumab vedotin)
  • Xpovio (selinexor)
  • Yescarta (axicabtagene ciloleucel)
  • Zynlonta (loncastuximab tesirine)

Methodology:

FirstView reports are developed from quantitative surveys conducted with physicians selected through LiMATM, the world's largest physician directory, containing over 3 million vetted and verified physicians. Each physician is carefully chosen based on strict screening criteria to ensure the insights gathered are both relevant and reliable, reflecting the true sentiments and experiences of leading medical professionals. The findings are presented in a series of easy-to-interpret charts, enabling you to quickly grasp and analyze the data. By leveraging the vast reach and precision of LiMATM, FirstView Reports provide unparalleled, data-driven insights to guide your strategic planning and help you stay ahead in a fast-evolving healthcare landscape.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.